Caribou Biosciences, Inc. (NASDAQ:CRBU) Short Interest Update

Caribou Biosciences, Inc. (NASDAQ:CRBUGet Free Report) was the target of a large increase in short interest in June. As of June 15th, there was short interest totalling 12,270,000 shares, an increase of 6.6% from the May 31st total of 11,510,000 shares. Based on an average daily trading volume, of 2,310,000 shares, the short-interest ratio is currently 5.3 days. Approximately 15.4% of the company’s stock are sold short.

Caribou Biosciences Stock Up 0.6 %

Shares of CRBU stock opened at $1.60 on Wednesday. The company has a 50 day moving average price of $2.72 and a 200 day moving average price of $4.71. Caribou Biosciences has a one year low of $1.54 and a one year high of $8.59.

Caribou Biosciences (NASDAQ:CRBUGet Free Report) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.07). Caribou Biosciences had a negative return on equity of 33.42% and a negative net margin of 345.05%. The firm had revenue of $2.43 million for the quarter, compared to analyst estimates of $3.00 million. Equities analysts predict that Caribou Biosciences will post -1.8 earnings per share for the current year.

Institutional Trading of Caribou Biosciences

A number of institutional investors have recently modified their holdings of the company. Trexquant Investment LP raised its position in Caribou Biosciences by 141.0% in the third quarter. Trexquant Investment LP now owns 214,144 shares of the company’s stock valued at $1,024,000 after purchasing an additional 125,277 shares during the period. Laurion Capital Management LP acquired a new position in shares of Caribou Biosciences during the third quarter worth $790,000. Vanguard Group Inc. boosted its stake in shares of Caribou Biosciences by 49.3% in the third quarter. Vanguard Group Inc. now owns 3,822,151 shares of the company’s stock valued at $18,270,000 after purchasing an additional 1,261,920 shares during the period. Exchange Traded Concepts LLC grew its holdings in Caribou Biosciences by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 23,924 shares of the company’s stock valued at $137,000 after purchasing an additional 6,066 shares in the last quarter. Finally, Thrive Wealth Management LLC purchased a new stake in Caribou Biosciences during the 4th quarter worth $183,000. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on CRBU shares. HC Wainwright cut their price target on Caribou Biosciences from $24.00 to $9.00 and set a “buy” rating on the stock in a research report on Tuesday, June 4th. Truist Financial reaffirmed a “buy” rating and issued a $19.00 target price on shares of Caribou Biosciences in a research note on Thursday, May 16th. Finally, Evercore ISI cut Caribou Biosciences from an “outperform” rating to an “inline” rating and cut their price target for the stock from $13.00 to $3.00 in a report on Monday, June 3rd.

Check Out Our Latest Report on Caribou Biosciences

Caribou Biosciences Company Profile

(Get Free Report)

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.

Read More

Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with's FREE daily email newsletter.